India’s NPPA identifies 634 non-compliant drug pricings

pharmafile | February 24, 2017 | News story | Medical Communications, Sales and Marketing Abbott, AstraZeneca, Cipla, Dr Reddy's, Dr Reddy’s, nppa 

India’s National Pharmaceutical Pricing Authority (NPPA) has revealed that as many as 634 drugs from top pharma firms in the country including AstraZeneca, Abbott, Cipla and Dr Reddy’s are suspected to be non-compliant with its ceiling prices.

The list was compiled from pricing data gathered in December last year, according to the institution. The authority has so far notified the prices of 622 medicines under revised Schedule-I of DPCO 2013 (National List of Essential Medicines NLEM -15).

The NPPA’s remit includes designating, monitoring and revising prices of pharmaceutical products. Its ceiling prices are defined by the average price of all drugs in a specified therapeutic area which have sales of more than 1%. The government then uses this calculation to fix the prices of essential treatments, with pharmaceutical firms permitted to raise the prices by 10% annually.

Among the drugs highlighted on the list are Abbot’s hyperthyroidism treatment Thyrocab and Alembic and Cipla’s antibiotic medicines Althrocin and Novamox respectively.

Matt Fellows

Related Content


AstraZeneca’s Ultomiris approved in Japan for prevention of relapses in patients with NMOSD

AstraZeneca has announced that Ultomiris (ravulizumab) has been approved in Japan as a long-acting C5 …


AstraZeneca shares oncology data at ASCO 2023

AstraZeneca plans to share data from its oncology pipeline at the American Society of Clinical …

FDA approves Abbott’s Assert-IQ insertable cardiac monitor

Abbott has announced that the US Food and Drug Administration (FDA) has granted its clearance …

Latest content